📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Zydus Receives Final USFDA Approval for Eltrombopag Tablets with $1.26 Billion Market Size
Zydus Lifesciences has received final USFDA approval for Eltrombopag Tablets (12.5 mg, 25 mg, 50 mg, and 75 mg), a generic version of Promacta. This is a high-value approval as the product had annual US sales of approximately USD 1,262.5 million as of November 2025. The tablets, used for treating low platelet counts, will be manufactured at the company's SEZ facility in Ahmedabad. This approval adds to Zydus's robust US portfolio, which now stands at 429 approvals.
Key Highlights
Received final USFDA approval for Eltrombopag Tablets in 12.5 mg, 25 mg, 50 mg, and 75 mg strengths.
Target market for Eltrombopag (Promacta) estimated at USD 1,262.5 million in annual US sales per IQVIA MAT Nov-2025.
Manufacturing will be handled at the group's formulation facility at SEZ, Ahmedabad.
Zydus now has a total of 429 approvals and has filed 505 ANDAs since FY 2003-04.
💼 Action for Investors
Investors should monitor the launch timeline and market share capture in the US, as this high-value product could significantly contribute to top-line growth. The approval reinforces Zydus's strong execution capabilities in the complex generics space.
Zydus Lifesciences' Subsidiary Receives USFDA Approval for ZYCUBO® for Menkes Disease
Zydus Lifesciences' U.S. subsidiary, Sentynl Therapeutics, has secured FDA approval for ZYCUBO® (copper histidinate), the first and only treatment for Menkes disease in the United States. Clinical trials demonstrated a significant nearly 80% reduction in the risk of death, with median overall survival reaching 177.1 months compared to just 17.6 months for untreated patients. This approval marks a major milestone for Zydus's rare disease portfolio, following its acquisition of the therapy from Cyprium Therapeutics in 2023. The drug holds Breakthrough Therapy and Orphan Drug designations, positioning Zydus as a leader in this niche therapeutic area.
Key Highlights
ZYCUBO® is the first and only FDA-approved therapy for Menkes disease, a rare and fatal genetic condition.
Clinical data showed an 80% reduction in death risk with median survival of 177.1 months vs 17.6 months for the control group.
The therapy has been granted Orphan Drug Designation by both the USFDA and the European Medicines Agency.
Estimated birth prevalence of Menkes disease is as high as 1 in 8,664 live male births.
The drug was acquired from Cyprium Therapeutics in 2023 and has successfully completed the final stages of development.
💼 Action for Investors
Investors should view this as a significant positive for Zydus's U.S. specialty business, as it provides a first-mover advantage in a rare disease market. Monitor the commercial launch and pricing strategy for ZYCUBO® to assess its long-term revenue impact.
Zydus Lifesciences ESG Score Improves to 83/100 in 2025 S&P Global Assessment
Zydus Lifesciences has announced a notable improvement in its Environmental, Social, and Governance (ESG) performance for the year 2025. According to the S&P Global Corporate Sustainability Assessment (CSA), the company's score increased to 83 out of 100. This marks a significant rise from the previous year's score of 78 out of 100. Such improvements are generally viewed favorably by institutional investors and global sustainability-focused funds.
Key Highlights
S&P Global released the Corporate Sustainability Assessment (CSA) ESG Score for 2025.
Zydus Lifesciences achieved an ESG score of 83/100 for the current assessment year.
The company recorded a 5-point improvement compared to the previous year's score of 78/100.
Higher ESG scores can lead to better access to capital and improved institutional investor sentiment.
💼 Action for Investors
Investors should recognize this as a positive sign of the company's commitment to sustainable business practices and governance. While it doesn't impact short-term earnings, it strengthens the long-term investment thesis for ESG-focused portfolios.
Zydus Lifesciences Extends Sterling Biotech API Acquisition Deadline to June 30, 2026
Zydus Lifesciences has announced a further extension for the acquisition of the API business of Sterling Biotech Limited (SBL). The transaction, which was previously extended to December 31, 2025, is now expected to be completed on or before June 30, 2026. This delay is attributed to SBL still being in the process of completing certain conditions precedent required under the Business Transfer Agreement. While the deal remains on track, the repeated extensions suggest a complex carve-out or regulatory process for the target business.
Key Highlights
Closing date for the acquisition of Sterling Biotech's API business extended to June 30, 2026.
This is a further extension from the previous revised deadline of December 31, 2025.
The delay is due to pending conditions precedent that must be fulfilled by the seller, Sterling Biotech Limited.
The original Business Transfer Agreement (BTA) for this acquisition was executed on September 17, 2024.
💼 Action for Investors
Investors should remain cautious as repeated delays in M&A execution can postpone projected synergies and growth in the API segment. Monitor for any changes in deal valuation or further extensions that might indicate deeper structural issues with the target assets.
Zydus Partners with Bioeq for US Launch of Lucentis Biosimilar; USFDA Approved
Zydus Lifesciences has entered into a strategic partnership with Swiss-based Bioeq to commercialize NUFYMCO®, an interchangeable biosimilar to Lucentis® (Ranibizumab), in the U.S. market. The USFDA approved the Biologics License Application (BLA) for the product on December 18, 2025, marking a significant milestone for Zydus's U.S. biosimilar portfolio. Under the agreement, Bioeq will handle manufacturing and supply while Zydus will lead commercialization efforts. This partnership targets a U.S. market opportunity for Ranibizumab biosimilars estimated at $210 million.
Key Highlights
Strategic partnership with Bioeq for U.S. commercialization of NUFYMCO®, an interchangeable biosimilar to Lucentis®.
USFDA approved the BLA for NUFYMCO® on December 18, 2025, confirming its interchangeable status.
The total addressable market for Ranibizumab biosimilars in the U.S. is approximately $210 million per IQVIA MAT Sep 2025.
Zydus will leverage its distribution network and marketing capabilities for the U.S. launch.
This follows a recent partnership with Formycon AG for a biosimilar of Keytruda®, signaling aggressive biosimilar expansion.
💼 Action for Investors
Investors should monitor the commercial rollout and market share capture in the U.S. ophthalmology segment as Zydus builds its high-margin biosimilars pipeline. The 'interchangeable' status is a key competitive advantage that could drive faster pharmacy-level substitution.
Zydus Signs Exclusive Pact with Myriad Genetics to Launch Cancer Diagnostic Tests in India
Zydus Lifesciences has entered into an exclusive agreement with US-based Myriad Genetics to introduce advanced cancer-risk assessment tests in India. The partnership includes the MyRisk® Hereditary Cancer Test, which analyzes 63 clinically significant genes to estimate lifetime risk for over 11 types of cancer. Additionally, Zydus will market the MyChoice® HRD Plus for ovarian cancer and Prolaris® for prostate cancer prognosis. This move significantly strengthens Zydus' precision oncology portfolio and its emerging MedTech franchise by leveraging globally validated diagnostic platforms.
Key Highlights
Exclusive agreement to market Myriad Genetics' globally validated diagnostic platforms in India.
Launch of MyRisk® test analyzing 63 genes (including BRCA1/2) to predict 5-year and lifetime cancer risks.
Introduction of MyChoice® HRD Plus and Prolaris® tests for personalized treatment of ovarian and prostate cancers.
Strategic expansion into the high-margin precision medicine and genomic decision-support tool market.
💼 Action for Investors
This partnership enhances Zydus' specialty healthcare offerings and provides a new growth lever in the diagnostic space. Investors should monitor the commercial rollout and adoption rates among Indian oncologists as a sign of successful diversification into MedTech.
Zydus Lifesciences: FDA Accepts CUTX-101 NDA Resubmission for Menkes Disease
Zydus Lifesciences' wholly-owned subsidiary, Sentynl Therapeutics, announced that the FDA has accepted the resubmission of its New Drug Application (NDA) for copper histidinate (CUTX-101) to treat Menkes disease in pediatric patients. The FDA has set a new PDUFA target action date of January 14, 2026. The original CRL cited cGMP compliance observations at the manufacturing site but did not raise concerns about CUTX-101's efficacy or safety data, which previously demonstrated an almost 80% reduction in the risk of death compared to an untreated control group. If approved, CUTX-101 will be the first FDA-approved treatment for Menkes disease.
Key Highlights
FDA accepted NDA resubmission for CUTX-101 on December 15, 2025
New PDUFA target action date is January 14, 2026
CUTX-101 demonstrated nearly 80% reduction in risk of death in clinical trials
Menkes disease impacts an estimated 1 in 34,810 to 1 in 8,664 live male births
Median overall survival was 177.1 months for CUTX-101 ET cohort compared to 16.1 months for the untreated historical control cohort
💼 Action for Investors
Investors should monitor the FDA's decision on CUTX-101 by January 14, 2026, as approval would be a significant positive catalyst for Zydus Lifesciences, given the unmet need for Menkes disease treatment.
Zydus Lifesciences: Shareholders approve fundraising with 99.89% majority
Zydus Lifesciences Limited announced the results of its postal ballot, revealing that shareholders have approved the special resolution for fundraising activities and issuance of securities. A significant 99.89% of votes were cast in favor of the resolution, while only 0.11% voted against. The remote e-voting process was conducted as per the Companies Act, 2013, with the voting period concluding on December 12, 2025. This approval enables Zydus Lifesciences to proceed with its fundraising plans.
Key Highlights
99.89% of votes were in favor of the special resolution for fundraising.
0.11% of votes were against the special resolution.
Remote e-voting concluded on December 12, 2025.
1706 members voted in favor through remote e-voting.
923141736 votes were cast in favor of the resolution.
💼 Action for Investors
The approval for fundraising activities suggests potential growth opportunities for Zydus Lifesciences; investors should monitor the company's plans for utilizing these funds and their impact on future performance.
Zydus Lifesciences Launches Zyrifa (Denosumab Biosimilar) at MRP Rs 12,495
Zydus Lifesciences has launched 'Zyrifa', a biosimilar of Denosumab (120 mg SC), to treat bone metastases in cancer patients. The product is priced at an MRP of Rs 12,495 and targets a significant patient base, as 50-70% of advanced breast and prostate cancer patients suffer from bone involvement. This launch strengthens Zydus's oncology portfolio, which already includes various biosimilars for solid tumors and blood cancers. By offering an affordable alternative for critical care, Zydus aims to capture a larger share of the domestic oncology market.
Key Highlights
Launched 'Zyrifa' (Denosumab 120 mg SC) for treating skeletal complications in cancer patients
Product priced at an MRP of Rs 12,495 to improve affordability and access
Targets a high-need segment where 50-70% of advanced breast/prostate cancer patients develop bone metastases
Expands Zydus's existing oncology biosimilar portfolio across multiple solid tumors
Zydus employs 1,500 scientists focused on R&D to drive such innovation-led launches
💼 Action for Investors
Investors should monitor the market penetration of Zyrifa as it strengthens Zydus's position in the high-margin biosimilars segment. The launch is a positive development for long-term growth in the oncology vertical.
Zydus Lifesciences Receives USFDA EIR for Jarod Injectable Facility with VAI Status
Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the USFDA for its injectable manufacturing facility located at Jarod, Vadodara. The inspection, which took place from August 25 to September 5, 2025, resulted in a 'Voluntary Action Indicated' (VAI) classification. This is a crucial milestone as it follows a Warning Letter issued by the USFDA on August 29, 2024. The VAI status suggests that the facility is now in a state of compliance, potentially clearing the path for new product approvals from this site.
Key Highlights
Received EIR for the Jarod injectable facility following a GMP follow-up inspection.
Facility classified as Voluntary Action Indicated (VAI) by the USFDA.
Inspection conducted between August 25 and September 5, 2025.
Resolution follows a Warning Letter previously issued on August 29, 2024.
Clears regulatory hurdles for future product launches from the Vadodara site.
💼 Action for Investors
Investors should view this as a significant de-risking event for the company's US injectable pipeline. The resolution of the Warning Letter improves growth visibility for the US market.